The Effects of Long-Term Treatment on Left Ventricular Hypertrophy in Patients with Essential Hypertension: Relation to Changes in Neurohumoral Factors

1997 ◽  
Vol 30 (5) ◽  
pp. 643-648 ◽  
Author(s):  
Hitoshi Ueno ◽  
Masanobu Takata ◽  
Shin Tomita ◽  
Shinya Oh-hashi ◽  
Kotaro Yasumoto ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Term Treatment ◽  
Left Ventricular ◽  
Long Term Treatment

scholarly journals Regression of left ventricular hypertrophy with long-term treatment of nifedipine in systemic hypertension

1994 ◽  
Vol 17 (11) ◽  
pp. 615-618 ◽  
Author(s):  
Tetsu Yamakado ◽  
Shinobu Teramura ◽  
Takahiro Oonishi ◽  
Mitsugu Maeda ◽  
Takeshi Nakano
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Term Treatment ◽  
Left Ventricular ◽  
Systemic Hypertension ◽  
Long Term Treatment

Evolution of Left Ventricular Hypertrophy and Function During Long-Term Treatment of Systemic Hypertension With Enalapril

1997 ◽  
Vol 79 (3) ◽  
pp. 373-376 ◽  
Author(s):  
Jose Ramón González-Juanatey ◽  
Antonio Pose Reino ◽  
Alfonso Varela Román ◽  
José María García Acuña ◽  
Jesús Alberto Fernández López ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Term Treatment ◽  
Left Ventricular ◽  
Systemic Hypertension ◽  
Long Term Treatment ◽  
And Function

scholarly journals Levels of Serum sST2, MMP-3, and Gal-3 in Patients with Essential Hypertension and Their Correlation with Left Ventricular Hypertrophy

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Xueling Wang ◽  
Wei Han ◽  
Lin Han ◽  
Jiyuan Yang ◽  
Kehui Li ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Essential Hypertension ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Matrix Metalloproteinase 3 ◽  
Insidious Onset ◽  
Galectin 3 ◽  
Increased Pressure

Essential hypertension (EH) is a clinically frequent cardiovascular disease, with insidious onset, causing increased pressure load and neuroregulation disorders in patients. Long-term EH can cause left ventricular hypertrophy (LVH), which can lead to arrhythmia and even death. The soluble suppression of tumorigenicity 2 (sST2), matrix metalloproteinase-3 (MMP-3), and galectin-3 (Gal-3) in serum plays an important role in the occurrence, development, and prognosis of cardiovascular diseases. In our study, we divided EH patients into 3 levels and groups with or without LVH, according to their condition. The levels of sST2, MMP-3, and Gal-3 in the serum were measured in different groups of patients. Our results showed that the levels of sST2, MMP-3, and Gal-3 in the serum increased progressively with the level in different EH groups. The levels of sST2, MMP-3, and Gal-3 in the serum of the LVH group were higher than those of the NLVH group, and it is positively correlated with LVH-related indexes. The risk of developing and progressing to LVH in patients with EH can be determined by the method of measuring three indicators.

Sign in / Sign up

Export Citation Format

Share Document